

**Remarks/Arguments:**

Applicants have taken this opportunity to amend the claims. Specifically we have amended claim 1 to cover compounds where R<sup>3</sup> is hydrogen or halo only. Basis for this amendment is to be found in the published application at paragraph [0095].

Applicants note the Examiners amendment attached to the Notice of Allowance dated 04/05/2006. The errors the Examiner is referring to were in fact corrected in the Preliminary Amendment filed 04/19/2005, but the strikethrough was not very clear in the scanned version received by the Examiner. The revisions have been accepted in the version above and Claims 12 and 13 are now in the form required by the Examiner.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Respectfully submitted,

/Lucy Padget/

---

Name: Lucy Padget  
Dated: 14<sup>th</sup> April 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451